2230273-76-2 ((Safimaltib)

L9790S42AI;1-(1-Oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide;1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carb;Safimaltib;example 158 (WO2018119036A1);F82983;SAFIMALTIB [INN];SCHEMBL20264893;UNII-L9790S42AI;MS-28615;DA-54553;1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide;MALT1 Inhibitor JNJ-67856633;Safimaltib [WHO-DD];example 158 [WO2018119036A1];SCHEMBL23417687;JNJ-67856633;HY-139399;JNJ67856633;CHEMBL5095244;GTPL11883;1-(1-Oxo-1,2-dihydro-5-isoquinolyl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)-4-pyridyl]pyrazole-4-carboxamide;1H-Pyrazole-4-carboxamide, 1-(1,2-dihydro-1-oxo-5-isoquinolinyl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)-4-pyridinyl]-;Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor JNJ-67856633;CS-0200367;EX-A5146;APWRZPQBPCAXFP-UHFFFAOYSA-N;AKOS040755403;JNJ 67856633;GLXC-26576;MFCD34475932;1H-PYRAZOLE-4-CARBOXAMIDE, 1-(1,2-DIHYDRO-1-OXO-5-ISOQUINOLINYL)-5-(TRIFLUOROMETHYL)-N-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)-;SY308706;2230273-76-2;JNJ-67856633 [WHO-DD];

MFCD34475932

APWRZPQBPCAXFP-UHFFFAOYSA-N

1S/C20H11F6N5O2/c21-19(22,23)15-8-10(4-6-27-15)30-18(33)13-9-29-31(16(13)20(24,25)26)14-3-1-2-12-11(14)5-7-28-17(12)32/h1-9H,(H,28,32)(H,27,30,33)

FC(C1=C(C(NC2C=CN=C(C(F)(F)F)C=2)=O)C=NN1C1=CC=CC2C(NC=CC1=2)=O)(F)F